Skip to content

Cryptosporidiosis and Enteropathogens in Bangladesh

Field Studies of Cryptosporidiosis and Enteropathogens in Bangladesh

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02764918
Enrollment
150
Registered
2016-05-06
Start date
2024-10-01
Completion date
2029-10-31
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cryptosporidiosis

Brief summary

The purpose of this study is to explore the role of anti-parasite antibody in protection of children from the parasitic infection cryptosporidiosis. This work has the promise of identifying immune pathways important for protection from parasitic infections of the gut, and will help with designing a vaccine to prevent this infection estimated to cause, from diarrhea and malnutrition, an overall burden of 12 million disability-adjusted life-years in children.

Interventions

None listed

Sponsors

International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 7 Days
Healthy volunteers
Yes

Inclusion criteria

* Mother willing to sign informed consent form. * Healthy infant * No obvious congenital abnormalities or birth defects. * Stable household with no plans to leave the area for the next one year.

Exclusion criteria

* Parents are not willing to have child's blood drawn. * Parents are planning to enroll child into another interventional clinical study during the time period of this trial that could affect the outcomes of this study. * Mother not willing to have blood drawn and breast milk extracted. * Parents not willing to have field research assistant in home two times per week. * History of seizures or other apparent neurologic disorders. * Infant has any sibling currently or previously enrolled in this study, including a twin.

Design outcomes

Primary

MeasureTime frameDescription
Functional characterization of anti-Cryptosporidium antibodies associated with protectionBirth until 4 yearsMeasure antibody isotype and subclass, mucosal (stool) vs systemic (plasma), complement fixation and opsonophagocytosis using bead-based multiplex immunoassays.

Secondary

MeasureTime frameDescription
Polymerase chain reaction (PCR) testing for diarrheal pathogens during acute infectionBirth to 4 years oldTo be conducted on children's acute and convalescent stool during diarrheal episodes.
Determine the role of circulating T follicular helper (cTfh) cells in induction of antibody responseThrough collection of blood specimens on day 0, 14 and 28 during acute infection.Use Activation Induced Marker (AIM) assays to test parasite infection-dependent changes in the activation, frequency, and immunophenotype of circulating Tfh cells.
Determination of maternal humoral response and impact on child infection/immunityOn enrollment (all) and 4 months (breast milk only).Collect mother blood, stool and breast milk on enrollment. Collect second breast milk at 4 months.
In depth characterization of Cryptosporidium antigens recognized by the child humoral immune responseBirth until 4 years.Utilize this longitudinal study of children and a Cryptosporidium protein microarray to probe plasma for the breadth of antigens recognized as well as the specific antigens to which children respond as they develop protective immunity.
Determine child anthropometric measuresEvery 6 months until 4 yearsCollect height, weight, mid-upper arm circumference.
Socioeconomic status questionnaireAt enrollmentTo be conducted on mothers.
Household sanitation questionnaireAt enrollmentTo be conducted on mothers.
Surveillance polymerase chain reaction (PCR) testing for diarrheal pathogensBirth until 4 years.To be conducted on child non diarrheal stool collected twice monthly.

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026